Drug-Eluting Stents vs. Coronary Artery Bypass Grafts in Patients with Diabetes

Results of ARTS-II show a clear benefit of DES over BMS but are inconclusive on the equivalence of DES and CABG.

In previous studies, percutaneous coronary intervention has demonstrated a safety profile similar to that of coronary artery bypass grafting but has also demonstrated a greater need for repeat revascularization, particularly in patients with diabetes. In this report, investigators (1) provide the 3-year outcome results for diabetic patients in the Arterial Revascularization Therapies Study — Part II (ARTS-II), a nonrandomized study of sirolimus-eluting stenting; and (2) compare the findings with those of the randomized treatment arms of the ARTS-I study of bare-metal stenting (BMS) versus CABG. The primary safety endpoint was a composite of death, MI, and cerebrovascular accident. The composite efficacy endpoint was the primary safety endpo…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)